Ovarian cancer is the most lethal gynaecological malignancy, because most patients are not diagnosed until the disease is at an advanced stage. However, prognosis is favourable if diagnosed when the disease is confined to the ovary. Therefore, a screening method that facilitates early detection has been actively sought ([@bib6]). Two diagnostic tests, transvaginal ultrasonography and the serum cancer antigen (CA)-125 assay, have been used for ovarian cancer screening ([@bib33]; [@bib18]; [@bib13]; [@bib38]; [@bib23]; [@bib2]). These two diagnostic tests have been able to detect many cases of early-stage ovarian cancer; however, a recent randomised study using these two tests failed to show mortality reduction ([@bib2]), the critical metric for screening success. That study also indicated that diagnostic evaluation following a false-positive screening test result was associated with increased morbidity.

The premise underlying the early detection of ovarian cancer by ultrasonography is the presence of a detectable ovarian mass. Low-grade serous, endometrioid, clear cell, and mucinous carcinomas develop from detectable precursor lesions in the ovary ([@bib14], [@bib32]). However, accumulating evidence suggests that this premise is inaccurate for many cases of high-grade serous carcinoma (HGSC). A large proportion of serous carcinomas have been shown to develop from tiny lesions in the fallopian tube ([@bib5]; [@bib28]; [@bib9]; [@bib22]; [@bib4]; [@bib17]), not in the ovary, and the vast majority of serous carcinomas are high grade ([@bib32]; [@bib29]). Thus, screening using transvaginal ultrasonography and the CA-125 assay is ineffective for the early detection of most HGSCs ([@bib13]; [@bib11]). Because HGSC is the most common and the most lethal type of ovarian cancer ([@bib11]), early detection of HGSC is necessary for reducing mortality due to ovarian cancer.

If most HGSCs arise in the fallopian tube, malignant cells shed by these cancers can be detected by the examination of cytological samples from the endometrial cavity (endometrial cytological testing), a concept similar to that for the detection of cervical cancers by Papanicolaou smears. Several case reports have shown that endometrial cytological tests developed to screen endometrial cancer ([@bib8]; [@bib3]) can detect intraepithelial and microinvasive fallopian tube carcinomas ([@bib15]; [@bib20]; [@bib24]; [@bib12], [@bib21]). In Japan, endometrial cancer screening using such cytological tests is widely performed for women at risk of the disease ([@bib37]), including breast cancer patients treated with tamoxifen ([@bib12]; [@bib26]), and women who request the screening. In the present study, we examined the data of patients with epithelial ovarian, fallopian tube, and primary peritoneal cancer to evaluate the role of endometrial cytological testing in detecting HGSC, particularly for screening setting.

Patients and methods
====================

A consecutive series of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer diagnosed and treated at the Department of Gynecology, Kameda Medical Center, Kamogawa, Chiba, Japan between January 2000 and July 2011 were identified from the tumour registry, and their medical records were reviewed to obtain clinical and pathological data. Of these patients, those who underwent pre-treatment endometrial and cervicovaginal cytological tests were included in this study. Patients with synchronous endometrioid endometrial cancer or patients with borderline ovarian tumour were excluded.

For endometrial cytological evaluation, samples were obtained from the endometrial cavity using a disposable plastic brush (endometrial sampler) as previously described by other authors ([@bib8]; [@bib3]). The samples obtained were smeared directly on slides for fixation and staining. In this study, a positive result was defined as the detection of malignant cells on cytological tests, and a suspicious result was defined as the identification of atypical but not malignant cells.

In asymptomatic women, endometrial cytological tests were performed to screen for endometrial cancer in addition to pelvic examination and cervicovaginal smears for cervical cancer screening. According to the records examined in this study, imaging studies such as transvaginal ultrasonography were also performed in some women. Symptomatic women with suspected ovarian, fallopian tube, or primary peritoneal cancer who visited the clinic underwent both endometrial cytological and cervicovaginal cytological tests, in addition to physical examination and transvaginal ultrasonography. For these symptomatic cases, cytological testing was performed to determine the nature of their disease before treatment. Endometrial and endocervical curettage was performed for women with positive or suspicious results on endometrial cytological testing to histologically confirm or rule out a diagnosis of endometrial cancer. Both asymptomatic women with screen-detected abnormalities and symptomatic women with suspected ovarian, fallopian tube, or primary peritoneal cancer underwent pre-treatment evaluation that included a serum CA-125 assay and imaging studies such as computed tomography (CT) of the abdomen and pelvis, as well as pelvic magnetic resonance imaging. In the recent past, whole-body positron emission tomography -CT has been performed instead of CT for some patients. In patients with bulky metastatic diseases (presumed stage III or IV) that did not appear to be optimally debulked by primary surgery, neoadjuvant chemotherapy was performed. Statistical analysis of the results was performed using the chi-square test and the Fisher\'s exact test.

Results
=======

Of the 188 patients with ovarian, fallopian tube, or primary peritoneal cancer who were diagnosed and treated during the study period, 122 patients underwent both endometrial and cervicovaginal cytological tests. The median age of the patients was 59 years (range, 33--83 years). Stage distribution was as follows: stage I, 37 patients (30%); stage II, 12 patients (10%); stage III, 60 patients (49%); and stage IV, 12 patients (10%) ([Table 1](#tbl1){ref-type="table"}). The remaining patient was classified as stage 0, because pathological examination showed no source of cancer in either the ovaries or fallopian tubes, but positive findings were observed for adenocarcinoma cells on peritoneal cytology. Forty-four patients (36%) had high-grade (grade 2--3) serous carcinoma. Seventy-eight patients had non-HGSC: 8 patients (7%) had low-grade serous carcinoma, 3 patients (2%) had non-gradable serous carcinoma, 32 patients (26%) had endometrioid carcinoma, 15 patients (12%) had clear cell carcinoma, 10 patients (8%) had mucinous carcinoma, and 10 patients (8%) had other histological types (including 1 patient with no detected source of carcinoma). Twelve patients (10%) were asymptomatic (screen-detected) ([Table 2](#tbl2){ref-type="table"}) and 110 patients (90%) were symptomatic.

Of the 122 patients, malignant cells were identified by cytological examination of samples from the endometrial cavity in 5 patients without detectable abnormalities on imaging studies. The characteristics of these five patients are listed in [Table 3](#tbl3){ref-type="table"}. Cytological examination was performed at other institutions for four asymptomatic patients and at our clinic for one symptomatic patient. We have previously reported on this symptomatic patient ([@bib25]).

In all the four asymptomatic patients with screen-detected ovarian, fallopian tube, or primary peritoneal cancer, endometrial cytological testing was positive for malignant cells, whereas cervicovaginal cytological testing was positive in only one of these patients. Two patients (cases 1 and 3) underwent surgery before the detection of abnormal findings on imaging studies. The case 1 patient underwent surgery 2 months after cytological detection; however, no source of cancer was detected (stage 0). This patient subsequently developed peritoneal carcinomatosis 3 years after primary treatment. In the other three patients, treatment was delayed, because their conditions could not be confirmed as gynaecological malignancy as repeated endometrial cytological testing results were not positive. One patient (case 3) had an elevated CA-125 level at the time of cytological testing (47 U ml^−1^); however, her CA-125 levels spontaneously decreased and remained within the normal range (⩽17 U ml^−1^) throughout the course of the study. All four diseases were diagnosed at an early stage (stage 0--II), and three gross tumours were diagnosed as HGSC by microscopic examination.

Of the 122 patients, endometrial cytological testing was positive in 15 patients (12%), including 5 patients (4%) who showed positive results on cervicovaginal cytology. Six of these 15 patients (40%) were diagnosed with early-stage disease (stage 0--II) ([Table 1](#tbl1){ref-type="table"}). Patients with HGSC were significantly more likely to have positive findings on endometrial cytology (10 out of 44, 23%) than those with other histological types (5 out of 78, 6% *P*=0.02). In the cases of low-grade serous or mucinous carcinomas, we found no positive or suspicious endometrial cytological findings.

Upon examination of the family history of 101 patients, we found that positive findings were observed on endometrial cytology more frequently in women who had a first-degree relative with breast or ovarian cancer (5 out of 12, 42%) than in women who did not (9 out of 89, 10% *P*=0.01). Of the five women with family histories of breast or ovarian cancer and positive findings on endometrial cytology, HGSC was observed in four and clear cell carcinoma was observed in one.

Discussion
==========

The findings of this study indicate that endometrial cytological testing can facilitate the detection of preclinical early-stage epithelial ovarian, fallopian tube, and primary peritoneal HGSCs during screening. Patients with HGSCs are more likely to have positive cytology findings than those with other histological types.

Epithelial ovarian cancers are heterogeneous and are classified into five main types: high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous tumours ([@bib29]). These types are essentially distinct diseases as indicated by the differences in epidemiological and genetic risk factors, precursor lesions, patterns of spread, and molecular events during tumourigenesis ([@bib32]; [@bib29]). Low-grade serous, endometrioid, clear cell, and mucinous carcinomas develop from detectable precursor lesions in the ovary, such as borderline tumours and endometriotic cysts ([@bib14]; [@bib32]). In contrast, many HGSCs appear to develop from tiny lesions in the fallopian tube.

A tubal origin of many HGSCs is supported by the following observations: (1) identification of the fallopian tube as a frequent source of early serous carcinoma on assessment of prophylactic salpingo-oophorectomy specimens from women with a germline mutation in the ovarian and breast carcinoma susceptibility genes (*BRCA1* or *BRCA2*) ([@bib28]; [@bib9]); (2) detection of serous carcinomas localised to the distal fallopian tube on microscopic examination of the entire fallopian tube in both *BRCA*-positive and *BRCA*-negative women ([@bib5]; [@bib9]; [@bib22]; [@bib4]; [@bib17]); and (3) identification of fallopian tube cancers more often than previously recorded in women at risk for developing ovarian cancer who undergo screenings using ultrasonography and the CA-125 assay ([@bib10]; [@bib18]; [@bib11]). Moreover, precursor lesions of epithelial cancer were found in the fallopian tube (tubal intraepithelial carcinoma (TIC)) ([@bib4]; [@bib17]; [@bib19]) but not on the ovarian surface ([@bib1]) in women with *BRCA* mutations who underwent prophylactic salpingo-oophorectomy. TIC is a lesion of several cell layers on the tubal mucosa and is a plausible precursor for many pelvic (ovarian, fallopian tube, and primary peritoneal) serous carcinomas ([@bib17]; [@bib19]; [@bib31]). Thus, screening tests need to be able to detect this microscopic lesion before it develops into a detectable mass and metastasises to the ovarian surface and/or pelvic peritoneum. Accordingly, ultrasonography screening cannot effectively detect HGSCs at an early stage, whereas other ovarian tumour histotypes, which remain in the ovary for an extended period, can be detected.

Serum CA-125 screening appears to be more effective than ultrasonography for detecting HGSC ([@bib11]). However, most HGSCs detected on the basis of elevated CA-125 levels are at an advanced stage ([@bib2]; [@bib11]), and therefore, CA-125 testing is not useful for detecting early-stage HGSCs.

Cytological testing of samples from the endometrial cavity is more useful than cervicovaginal cytological testing for detecting malignant cells shed by fallopian tube cancer. A study on fallopian tube carcinomas, most of which were presumed to be HGSCs, showed that the incidence of positive endometrial cytology findings (positive for malignant cells) was twice as high as that of positive cervicovaginal cytology findings (50% *vs* 25% [@bib36]). Although ovarian cancer has not been thought to be associated with positive cervical cytology ([@bib39]), a study on ovarian cancer showed that cervical cytology findings were positive in 19.3% of patients, which was less than half of the rate of positive findings on endometrial cytology (41.9% [@bib35]). However, the definition of positive cytological findings in that study was not available. A later study on ovarian cancer from the same institution showed lower incidences of positive findings on cytology (positive for adenocarcinoma cells): 11.7% for endometrial and 6.1% for cervical cytology ([@bib34]). In our study, which includes ovarian, fallopian tube, and primary peritoneal cancers, the incidence of positive findings on endometrial cytology was three times as high as that of positive findings on cervicovaginal cytology (12% *vs* 4%). Differences in positive rates among studies may reflect the difficulty in interpreting cytological findings.

Of note, histological examinations of tissue samples obtained by endometrial curettage could not detect preclinical ovarian, fallopian tube, or primary peritoneal cancer in our study ([Table 3](#tbl3){ref-type="table"}), thereby highlighting the importance of cytological testing for the detection of malignant cells shed by the adnexal lesions and present in the endometrial cavity. In contrast, in all the eight patients with endometrial cancer who did not show detectable abnormalities on transvaginal ultrasonography during the same period, the endometrial cancer was diagnosed by histological examination of tissue samples obtained by endometrial curettage. Of the 179 postmenopausal endometrial cancer patients, 8 (4.5%) did not show detectable abnormalities (an endometrial thickness ⩽5 mm; [@bib16]): 5 patients presented with vaginal bleeding and 3 patients without bleeding showed abnormal findings on endometrial cytological testing (data not shown).

Our study showed that women with family histories of breast or ovarian cancer were more likely to have positive cytology findings than women without such histories. Thus, endometrial cytological testing appears to be useful in these women, that is, women with a hereditary predisposition to ovarian cancer.

Endometrial cytological testing as an early detection method for HGSCs offers several advantages. First, this testing can detect HGSCs before they develop into a detectable mass. Even if HGSCs cannot be diagnosed at stage I, it is possible that they may be detected at a stage of low-volume disease, when they are still completely resectable. Second, direct sampling of tumour cells enables a cytology-based diagnosis. A high positive predictive value is expected when the lesion has progressed to HGSC with cells showing marked nuclear atypia. In addition, this cytological testing can be used in premenopausal women who tend to exhibit false-positive abnormalities on ultrasonography scans and CA-125 assays. Moreover, endometrial cytological smears are inexpensive, well tolerated by patients, and easily performed by gynaecologists in clinical settings ([@bib8]; [@bib3]; [@bib37]). Finally, this testing can detect endometrial carcinomas, which sometimes develop in women with breast cancer. However, in women with cervical stenosis, which is observed more often in elderly women, this method cannot be used.

In our study, the positive rate of endometrial cytological testing for stage I HGSC was low (1 out of 6, 17%). All six patients were diagnosed with ovarian carcinoma and five of them had an ovarian mass. An explanation for this low positive rate is that tubal occlusion caused by compression due to an ovarian mass or by tubal elongation associated with ovarian enlargement prevents clusters of cancer cells from flowing into the endometrial cavity. Another explanation is that some ovarian HGSCs arise from serous borderline tumour and low-grade serous carcinoma ([@bib7]), both of which are thought to develop within the cortical inclusion cyst of the ovary.

Several limitations of this study should be noted, in addition to the selection bias inherent to most retrospective reviews. First, pathological examination of TICs was not performed in all cases; therefore, the percentage of HGSCs that developed in the fallopian tube was unknown. However, the incidence of positive findings on endometrial cytology for HGSCs in our study (23%) was similar to that for TICs coexisting in these tumours (36%) ([@bib30]), taking into consideration the difficulty of cytological evaluation and possible sampling errors. Second, the sensitivity, specificity, and positive and negative predictive values of endometrial cytological testing could not be calculated accurately, because the screening status was not known in all the patients. In our study, at least 4 patients who underwent annual endometrial cytological testing were diagnosed with HGSC at an interval of 2--6 months after negative screening (1 stage IIc and 3 stage IIIc diseases), and thus sensitivity was estimated at 43% (3 out of 7) or less for HGSC. Third, *BRCA* testing, which is still uncommon in Japan partly because its high cost is not covered by health insurance, was not performed for any patients in this study. Therefore, the association between positive findings on endometrial cytology and *BRCA* mutation status could not be assessed.

Finally, and importantly, whether endometrial cytological testing can detect carcinomas early enough to improve outcome has yet to be determined. Cancer cells arising from the fallopian tube may have already spread throughout the peritoneal cavity even if the original lesion is intraepithelial or microinvasive carcinoma. Little information regarding long-term outcomes is available for most reported cases of cytology-detected fallopian tube cancer. However, a patient with serous TIC with positive findings on peritoneal cytology, who also had a personal history of breast cancer, survived for \>7 years despite two recurrences ([@bib12]). In our study, two of the four asymptomatic cytology-detected patients survived for ⩾5 years without a recurrence, even with delayed treatment.

In conclusion, efforts to detect early 'ovarian\' cancer should focus on detecting the most common and the most lethal type: HGSC. To detect HGSCs, many of which arise in the fallopian tube, examination of cytological samples from the endometrial cavity appears to be a promising method. High-grade endometrioid carcinomas, which have been reported to develop in the fallopian tube ([@bib22]; [@bib4], [@bib25]), may also be detected using this method. Although the sensitivity of this method may not be sufficiently high on using conventional cytological evaluation methods, the use of p53 staining, which can detect atypical cells in TIC and its precursor lesions ([@bib27]; [@bib5]; [@bib22]; [@bib19]), may be helpful for early diagnoses. Use of an aspiration method in combination with a brush method for obtaining cytological samples from the endometrial cavity may improve the detection rates of malignant cells. The effectiveness of endometrial cytological testing for early-stage HSGC detection may be evaluated by using this method as a preoperative test for prophylactic bilateral salpingo-oophorectomy in women at risk for developing HGSC. For women with a *BRCA* mutation or family histories of breast or ovarian cancer who hope to undergo ovarian cancer screening, this testing method may be used as a surveillance test in combination with transvaginal ultrasonography and the serum CA-125 assay to compare the effectiveness of these tests for HGSC detection. Thus, limiting screening to high-risk women may reduce the burden of diagnostic procedures. Further studies are needed to address the issues of early detection using this method, the acceptability of this technique, and the health economics associated with this testing method before it is incorporated into an ovarian cancer screening randomised controlled trial to evaluate its effect on reducing mortality due to the disease.
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###### Endometrial cytology results for high-grade serous and non-high-grade serous carcinoma

                                                           **High-grade serous carcinoma**   **Non-high-grade serous carcinoma**        
  ------------------------- ------------------------------ --------------------------------- ------------------------------------- ---- ------------------------------------
  **Stage**                                                                                                                             
  0                         1[a](#t1-fn1){ref-type="fn"}   0                                 0                                     1    1 (100%)
  I                         37                             6                                 1 (17%)                               31   0 (0%)
  II                        12                             4                                 2 (50%)                               8    2[b](#t1-fn2){ref-type="fn"} (25%)
  III                       60                             31                                7 (23%)                               29   2[c](#t1-fn3){ref-type="fn"} (7%)
  IV                        12                             3                                 0 (0%)                                9    0 (0%)
  **Ascites**                                                                                                                           
  None to minimal           84                             22                                6 (27%)                               62   4 (6%)
  Moderate to massive       38                             22                                4 (18%)                               16   1 (6%)
  **Peritoneal cytology**                                                                                                               
  Positive                  49                             28                                8 (29%)                               21   3 (14%)
  Suspicious                7                              2                                 0 (0%)                                5    0 (0%)
  Negative                  60                             11                                1 (9%)                                49   1 (2%)
  Unknown                   6                              3                                 1 (33%)                               3    1 (33%)

No source of cancer was detected.

Clear cell, 1; and endometrioid, 1.

Mixed (endometrioid and clear cell), 1; and non-gradable serous, 1.

###### Characteristics of screen-detected patients with epithelial ovarian, fallopian tube, and primary peritoneal cancer

                                                                                  **Detection method**      
  ----------------------------------------------------------------- -------- ------------------------------ ------------------------------
  **Age, years**                                                                                            
  Range                                                              54--69              54--69                         58--69
  Median                                                               62                  57                             64
  **Stage**                                                                                                 
  0                                                                    1      1[c](#t2-fn3){ref-type="fn"}                0
  I                                                                    2                   1                              1
  II                                                                   4                   2                              2
  III                                                                  3                   0                              3
  IV                                                                   2                   0                              2
  **Histology**                                                                                             
  High-grade serous                                                    6                   3                              3
  Non-high-grade serous                                                6      1[c](#t2-fn3){ref-type="fn"}   5[d](#t2-fn4){ref-type="fn"}
  **First-degree family history of breast and/or ovarian cancer**                                           
  Yes                                                                  5                   1                              4
  No                                                                   6                   3                              3
  Not available                                                        1                   0                              1

No abnormal findings on imaging studies.

Six tumours were detected by ultrasound, 1 by PET-CT (positron emission tomography--computed tomography), and 1 by pelvic examination.

No source of cancer was detected.

Endometrioid, 2; clear cell, 2; and low-grade serous, 1.

###### Cytology-detected patients with ovarian, fallopian tube, and primary peritoneal cancers who did not show abnormal findings on imaging studies at detection

  **Case**   **Age (years)**    **Past history/family history**   **Prevalent[a](#t3-fn3){ref-type="fn"}/incident[b](#t3-fn4){ref-type="fn"}/symptomatic**   **Endometrial cytology**   **Endometrial curettage**   **Cervicovaginal cytology**  **CA-125 level (U ml^−1^)**   **Time to treatment[c](#t3-fn5){ref-type="fn"} (months)**                    **Disease site**                    **Peritoneal cytology**   **Stage**         **Histotype** **Grade**         **Residual disease[d](#t3-fn6){ref-type="fn"}**   **Status**  **Follow-up after surgery (months)**
  ---------- ----------------- --------------------------------- ------------------------------------------------------------------------------------------ -------------------------- --------------------------- ----------------------------- ----------------------------- ----------------------------------------------------------- --------------------------------------------------- ------------------------- ----------- ------------------------------------- ------------------------------------------------- ------------ --------------------------------------
  1          58                      No cancer/lung Ca (B)                                               Prevalent                                                   Positive                   Negative                     Positive            10                            2                                                                              Not detected                             Positive               0                       NA                                         None                            DOD      59
  2          54                    No cancer/lung Ca (F, B)                                               Incident                                                   Positive                   Negative                     Negative            NA                            8                                                                               Ovary (Bil)                             Positive              IC                 Serous Grade 2                                   None                            NED      127
  3          55                  Breast Ca (Bil)/breast Ca (M)                                            Incident                                                   Positive                   Negative                     Negative            47                            12                                                                        Fimbria (Rt) Ovary (Lt)                       Positive              IIC                Serous Grade 2                                   None                            NED      63
  4          69                     No cancer/liver Ca (F)                                               Prevalent                                                   Positive                   Negative                    Suspicious           42                            30                                                           Fallopian tube (Lt)) Ovary (Lt) Pelvic peritoneum          Negative              IIB                Serous Grade 3                                  \<2 cm                           DOD      15
  5          64                    No cancer/breast Ca (GM)                                    Symptomatic (vaginal bleeding)                                        Positive                   Negative                     Negative            386                           3                                                                 Fimbria (Rt) Pelvic peritoneum Omentum                Positive             IIIB      Endometrioid Grade 3 and clear cell                       \<1 cm                           DOD      43

Abbreviations: B=brother; F=father; M=mother; GM=grandmother; NA=not available; Bil=bilateral; Rt=right; Lt=left; NED=no evidence of disease; DOD=dead of disease.

All patients were parous and postmenopausal. Taxane/carboplatin chemotherapy was given in all patients postoperatively.

Prevalent (cancer)=cancer detected during the first screening examination.

Incident (cancer)=cancer detected after a previous negative screen.

Time from cytological detection to treatment.

Residual disease at the completion of the initial surgery.
